These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15742548)

  • 41. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The importance of sequencing in treatment options.
    Berger DS
    Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
    [No Abstract]   [Full Text] [Related]  

  • 44. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy.
    Madeddu G; Calia GM; Campus ML; Lovigu C; Mannazzu M; Olmeo P; Mela MG; Mura MS
    Int J STD AIDS; 2008 Sep; 19(9):644-5. PubMed ID: 18725561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
    Bonjoch A; Negredo E; Puig J; Erkizia I; Puig T; Cabrera C; Ruiz L; Clotet B
    AIDS; 2006 Sep; 20(14):1896-8. PubMed ID: 16954734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 48. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 49. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
    Harris M; Larsen G; Montaner JS
    AIDS; 2008 Jun; 22(10):1224-6. PubMed ID: 18525270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 51. Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide.
    Lou J; Smith RJ
    J Theor Biol; 2011 Jan; 268(1):1-13. PubMed ID: 20888346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
    Youle M; Cohen C; Katlama C; Kuritzkes D; Walmsley S
    Lancet; 2004 Sep 18-24; 364(9439):1036-7. PubMed ID: 15380959
    [No Abstract]   [Full Text] [Related]  

  • 53. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.
    Brennan-Benson P; Pakianathan M; Rice P; Bonora S; Chakraborty R; Sharland M; Hay P
    AIDS; 2006 Jan; 20(2):297-9. PubMed ID: 16511429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Staphylococcus aureus brain abscess in an HIV-infected patient exposed to enfuvirtide.
    Denoeud L; Pacanowski J; Welker Y; Moulignier A; Girard PM
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(5):217-9. PubMed ID: 18701426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management.
    Murphy RL
    AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S12-8. PubMed ID: 19960652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 60. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.